Additionally, ApoA1 was demonstrated to decrease the viability of gastric adenocarcinoma cells in vitro, by abrogating the proliferation induced by LPA (Yeh et al., 2016), a pro-inflammatory pro-carcinogenic lysophospholipid that is crucially involved in the modulation of several intracellular pathways also contributing to ovarian cancer progression (Fang et al., 2002; Bast et al., 2009; Li et al., 2009; Fan et al., 2015; Riaz et al., 2016; Ottevanger, 2017). The gene discussed is APOA1; the disease is ovarian carcinoma.